Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study

1. Tokito, T.
2. Kolesnik, O.
3. Sørensen, J.
4. Artac, M.
5. Quintela, M.L.
6. Lee, J.-S.
7. Hussein, M.
8. Pless, M.
9. Paz-Ares, L.
10. Leopold, L.
11. Daniel, J.
12. Munteanu, M.
13. Samkari, A.
14. Xu, L.
15. Butts, C.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1186/S12885-023-11203-8 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus